ÖZET

Amaç:

Bu çalışmada amacımız, hipertansiyonun Koronavirüs hastalığı-2019 (COVİD-19) hastalarının klinik ağırlığı ve prognozu üzerine etkisini araştırmaktır.

Yöntemler:

Bu retrospektif gözlemsel çalışmaya Mart-Mayıs 2020 tarihleri arasında Bezmialem Vakıf Üniversitesi Hastanesi’nde yatarak izlenen 18 yaş üstü, ters transkripsiyon-polimeraz zincir reaksiyonu (RT-PCR) pozitif COVİD-19 hastalar dahil edildi. Hastalar hipertansif ve hipertansif olmayan olarak iki gruba ayrılarak klinik, laboratuvar ve prognoz açısından karşılaştırıldı.

Bulgular:

Çalışmaya dahil edilen 260 COVİD-19 hastasının %55,4’ü erkek, yaş ortalamaları (± standart sapma) 54,1±15,5’tir. Hipertansif hastalar daha yaşlıydı (64,6±11,5 ve 47,2±13,9) (p<0,001), daha yüksek diabetes mellitus oranlarına sahipti (%41,7 ve %11,5, p<0,001) ve kronik böbrek yetmezliği ile daha fazla komplike idi (%16,5’e karşı %2,5, p<0,001). Hipertansiyon olan grupta hastaların %56,1’i desatüre olurken (SaPO2<%93), hipertansiyon olmayan grupta bu oran %32,3 idi (p<0,001). Hipertansif hastaların %39,8’inde oksijen tedavisine ihtiyaç olmuşken, hipertansif olmayan hastalarda bu oran %25,5 idi (p=0,001). Hipertansif hastalarda yoğun bakım ünitesine yatış oranı (%23,3) ve hastane içi mortalite oranı (%17,5), hipertansif olmayan hastalardaki oranlara göre yüksekti (sırasıyla %11,5 ve %8,8) (p=0,01 ve p=0,025).

Sonuç:

Çalışmamız hipertansiyonu olan COVID-19 hastalarında kötü prognozu önlemek için ek dikkat göstermek gerektiğini göstermektedir.

References

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet . 2020;395:1054-62.

World Health Organization. Coronavirus disease (COVID-19). Situation report 142. June 2020 [June 2020]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200610-covid-19-sitrep-142.pdf?sfvrsn=180898cd_2.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020;180:934-43.

Wu JT, Leung K, Bushman M, Kishore N, Niehus R, de Salazar PM, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med 2020;26:506-10.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-3.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565-74.

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004;203:631-7.

Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol 2005;791:14614-21.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-ınfected pneumonia in Wuhan, China. JAMA 2020;323:1061-9.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020;367:1444-8.

Altun B, Arici M, Nergizoglu G, Derici Ü, Karatan O, Turgan Ç, et al. Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. J Hypertension 2005;23:1817-23.

Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res 2020:1-8.

Hui DS, Azhar EI, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020;91:264-6.

Zhou X, Zhu J, Xu T. Clinical characteristics of coronavirus disease 2019 (COVID-19) patients with hypertension on renin-angiotensin system inhibitors. Clin Exp Hypertens 2020;42:656-60.

Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J 2020;41:2058-66.

Wang S, Chen Y, Wang L, Liu H, Han P. Are COVID-19 patients with hypertension at higher risk in China? J Hypertens 2020;38:1384-5.

Morra ME, Van Thanh L, Kamel MG, Ghazy AA, Altibi AMA, Dat LM, et al. Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta-analysis. Rev Med Virol 2018;28:e1977.

Matsuyama R, Nishiura H, Kutsuna S, Hayakawa K, Ohmagari N. Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. BMC Public Health 2016;16:1203.

Kreutz R, Algharably EAE, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, et al. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res 2020;116:1688-99.

Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020;71:762-8.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:2620-9.

Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nat Rev Immunol 2019;19:517-32.

Hipertansiyonu Olan COVİD-19 Hastalarında Klinik Özelliklerin ve Prognozun Değerlendirilmesi: Tek Merkezli Retrospektif Gözlemsel Çalışma

ÖZET

References